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Background
Poxvirus based HIV vaccine candidates are currently under
evaluation in preclinical and clinical trials. Modified Vac-
cinia Virus Ankara (MVA) vectors have excellent safety
records and immunogenicity, but their behaviour in
human cell cultures remains partly characterized.
Methods
We studied here various virological and immunological
aspects of the interactions of an MVA-GagPolNef vaccine
candidate developed by the ANRS, with human DCs, lym-
phocytes, and other cell types.
Results
We report that MVA-GagPolNef efficiently infects a panel
of primary and immortalized human cells (including
macrophages, DCs, B, epithelial cells, muscular cells and
fibroblasts), and drives Gag expression in these cells.
Infection was cytopathic, and, as expected with this vector,
induced apoptosis within 1–2 days of infection. In con-
trast, primary T cells were more resistant to infection and
apoptosis. DCs infected with MVA-GagPolNef (and not
with a control MVA vector) presented HIV antigens and
activated HIV-specific CD8+ CTLs. The infection of DCs
by MVA induced cell maturation, secretion of various
cytokines, and was followed by apoptosis. Interestingly,
coculture of MVA-GagPolNef-infected epithelial cells with
DCs promoted efficient HIV-Gag antigen cross-presenta-
tion without inducing DC infection and cell death. Other
MVA-infected cells were similarly efficiently cross-pre-
sented by DCs to CD8 T cells. APCs exposed to MVA-Gag-
PolNef also activated HIV-specific CD4 T cells, indicating
that this vector promotes both MHC-I-restricted cross-
presentation and MHC-II-presentation of HIV antigens by
DCs. We also examined the impact of MVA-GaPolNef on
HIV replication in DC/T cell cocultures. Interestingly,
there was no enhancement of HIV transfer and replication
when MVA-GagPolNef was incubated with DCs prior to
infection with HIV, nor when MVA-infected cells were
added in the cocultures.
Conclusion
Altogether, these results strongly suggest that the highly
immunogenic properties of MVA vector are not associated
with an enhancement of HIV replication.
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